Genmab | GEN - Operating Profit


Genmab reported DKK260M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Almirall EUR 30.23M 12.8M Dec/2025
Amarin USD -2.26M 564K Dec/2025
Amgen USD 3.96B 464M Dec/2025
argenx SE USD 371.14M 21.17M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bayer EUR 1.11B 1.65B Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Demant DKK 2.09B 224M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Fresenius Medical Care EUR 663M 213.06M Dec/2025
Galapagos EUR 780.56M 822.23M Dec/2025
Genmab DKK 260M 199M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
GN Store Nord DKK 570M 230M Dec/2025
GRIFOLS EUR 275.38M 76.74M Dec/2025
Hikma Pharmaceutical USD 348M 161M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Lonza CHF 673M 243M Jun/2025
Merck EUR 474M 738M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
UCB EUR 1.29B 571M Dec/2025